MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Inter- and intra-day variability in β-Glucocerebrosidase activity and pathway biomarkers in healthy volunteers and patients with Parkinson’s disease with a GBA1 mutation

    J. Vandervalk, D. Dumas, E. Thijssen, D. Pereira, W. Grievink, Y. Yavuz, C. Pesch, D. Ysselstein, M. Hagey, J. Cedarbaum, K. Hunt, P. Kremer (Leiden, Netherlands)

    Objective: Characterize inter- and intra-day variability of β-glucocerebrosidase (GCase) activity, using a live-cell assay, and glucosyl-β sphingosine levels in healthy volunteers (HVs) and Parkinson’s disease…
  • 2024 International Congress

    Opicapone as Add-on to Levodopa in Parkinson’s Patients without Motor Complications: Preliminary Data from EPSILON

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, G. Castilla-Fernández, J. Rocha, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: The EPSILON study aimed to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa/dopa decarboxylase inhibitor (DDCi) in patients with…
  • 2024 International Congress

    The relationship between pain threshold and striatal dopamine function in Parkinson’s Disease

    H. Kawasaki, Y. Sakasai, S. Fujita, R. Yokoyama, K. Seo, Y. Ito, T. Yamamoto (moroyama, Japan)

    Objective: This study aims to determine the relationship between pain threshold and striatal dopamine function in people with Parkinson's disease. Background: About 40-85% of Parkinson's…
  • 2024 International Congress

    Effect of Istradefylline on Motor and Non-motor Symptoms in Patients with Parkinson’s Disease: the ISTRA ADJUST PD Randomized, Controlled Study

    H. Nagayama, T. Hatano, R. Sengoku, N. Yanagisawa, O. Kano (Tokyo, Japan)

    Objective: To examine the effects of istradefylline on motor and non-motor symptoms in Parkinson’s disease (PD) patients with wearing-off phenomena. Background: Previous results [1,2] of…
  • 2024 International Congress

    Opicapone as First-Line Strategy for the Treatment of Wearing-off in Korean Patients with Parkinson’s Disease

    J. Lee, J. Ferreira, H. Ma, J. Rocha, B. Jeon (Seoul, Republic of Korea)

    Objective: This study aimed to explore the efficacy of opicapone (OPC) 50 mg versus an extra 100 mg levodopa (L-dopa) dose to treat early wearing-off…
  • 2024 International Congress

    A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment

    N. Shanbhag, J. Padmanabhan, Z. Zhang, B. Harel, H. Jia, T. Kangarloo, W. Yin, A. Dowling, A. Laurenza, P. Khudyakov, K. Galinksy, R. Latzman, T. Simuni, D. Weintraub, F. Horak, C. Lustig, P. Maruff, A. Simen (Cambridge, USA)

    Objective: To study the safety and efficacy of TAK-071, an M1 positive allosteric modulator, in adults with Parkinson disease (PD) with increased risk for falls…
  • 2024 International Congress

    Assembling a Cohort of Hyposmic Participants for Therapeutic Studies Aimed at Parkinson’s Disease (PD) Prevention

    B. Mcmahon, L. Lemon, R. Dobkin, E. Brown, J. Dimos, M. Kuhl, L. Heathers (Baltimore, USA)

    Objective: The goal of this project was to amass a cohort of individuals with hyposmia to later invite them to participate in clinical trials for…
  • 2024 International Congress

    A Prospective, Multicenter, Single-Arm Feasibility Study Examining ECAP-Controlled, Closed-Loop Spinal Cord Stimulation for Parkinson’s Disease (eCAP-PD): Technical and Design Considerations

    L. Verhagen, T. Virmani, M. Pourfar, C. Hess, J. Rosenow, E. Petersen, A. Mogilner, J. Karl, N. Shetty (Chicago, USA)

    Objective: Conduct a prospective feasibility study to determine the effects of ECAP-controlled closed-loop spinal cord stimulation (SCS) on motor symptoms in Parkinson’s disease (PD) patients.…
  • 2024 International Congress

    A Randomized, Double-blind, Phase 2a Clinical Trial to Study the Efficacy and Safety of Lamotrigine for Treatment of Patients with Dementia with Lewy Bodies

    T. Xi, S. Kang, F. Kim, A. Schindler, D. Greeley, J. Choung, M. Yun, B. Ye (San Diego, USA)

    Objective: This proof-of-concept clinical trial will test the efficacy and safety of lamotrigine compared to placebo in patients with dementia with Lewy bodies (DLB). Background:…
  • 2024 International Congress

    Refining Aesthetic Eyebrows: Botulinum Toxin Injection for Hemifacial Spasm.

    S. Maytharakcheep, R. Bhidayasiri, O. Phokaewvarangkul (Bangkok, Thailand)

    Objective: To investigate the efficacy of botulinum toxin injection (BoNTA) in correcting eyebrow asymmetry in patients with hemifacial spasms (HFS). Background: HFS typically affects women…
  • « Previous Page
  • 1
  • …
  • 398
  • 399
  • 400
  • 401
  • 402
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley